

## **Zydus Cadila Total Income up by 20% in Q3**

---

Ahmedabad, February 7, 2012

For the third quarter ended 31<sup>st</sup> December 2011, Zydus Cadila registered a Total Income of Rs. 1401 crores up by 20% from Rs. 1170 crores in the corresponding period last year, on a consolidated basis. The Net Profit excluding the impact of foreign exchange fluctuations loss was up by 7% to Rs. 177 crores from Rs. 165 crores in the corresponding period last year.

During the quarter, the group's India formulations business grew by 18%. The group launched 15 new products, of which, 7 were the first in India. Strengthening its operations in the Indian pharma market, the group acquired the Mumbai based Biochem, one of India's top 40 pharma companies. Biochem is a strong player in the antibiotics, cardiovascular, anti-diabetic and oncological segments. Business of the JV companies posted a healthy growth of 58% during the quarter.

Riding high on the increased sales of its own products and that of the recently acquired Neshar, the group's subsidiary in the US posted a growth of 45%. The group also posted a growth of 44% in sales in Japan. The group filed 5 more ANDAs this quarter, taking the total to 141 ANDA filings. For the EU market, 9 new product dossiers were filed taking the cumulative to 132. The group received 8 new product approvals for the EU market taking the cumulative approvals to 82. During the quarter, 7 more products were supplied to Spain from India. The group now supplies 12 products to Spain. Additionally, the group filed 11 new product dossiers for the Brazilian market and 10 new product dossiers for the Mexican market, taking the cumulative to 79 and 14, respectively.

During the quarter, the group launched PegiHep, the first true biosimilar pegylated interferon alfa-2b in India. Used in the treatment of Hepatitis B & C, PegiHep is the fifth biosimilar product from the robust biologics pipeline developed at the Zydus Research Centre.

\*\*\*